New Protocols (10*)
Lung Carcinoma, Non-Small Cell
NHL, B-cell type, primary Lymphoma of the central nervous system
- Rituximab 375, primary lymphoma of the central nervous system PID 3277 V1.0 (2026-11-03)
- Rituximab 375 / Temozolomide 150, primary central nervous system Lymphoma, cycles 1–4 PID 3275 V1.0 (2026-11-02)
- Rituximab 375 / Temozolomide 150 - Temozolomide 150, primary central nervous system Lymphoma, cycles 5–12 PID 3276 V1.0 (2026-11-02)
- Pomalidomide 5 / Dexamethasone 40, primary central nervous system Lymphoma, cycles 1–2 PID 3279 V1.0 (2026-11-02)
- Pomalidomid 5 / Dexamethason 40 - Pomalidomid 5, primäres Lymphom des Zentralnervensystems, Zyklus Erhaltung PID 3280 V1.0 (2026-11-02)
- Ibrutinib 840, primary lymphoma of the central nervous system PID 3281 V1.0 (2026-11-02)
- Cytarabine 3000 / Zanubrutinib 160, primary lymphoma of the central nervous system PID 3282 V1.0 (2026-11-02)
Renal Cell Carcinoma
Pancreatic Cancer
Updated Protocols (5*)
Bladder Cancer
- Vinflunin 320, Bladder Cancer PID 563 V1.1 (2026-11-03)V1.1: Addition of antiemetic module in accordance with Guideline 2026 & modification of fluid module V1.0: Runtime according to primary literature; emetogenicity risk classified according to primary literature; fluid intake based on summary of product characteristics.
Hodgkin Lymphoma
- TEAM - Thiotepa 5 / Etoposide 100 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation PID 406 V2.1 (2026-11-03)V2.1: Changes to primary literature, nomenclature, hydration, antiemetics, and infection prophylaxis V2.0: Adjustment of antineoplastic therapy based on Ladetto et al. 2024. Correction to the antiemesis module for delayed vomiting. V1.0: Cato test done. OptiTemplate test done.
Mantle Cell Lymphoma
- TEAM - Thiotepa 5 / Etoposide 100 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation PID 406 V2.1 (2026-11-03)V2.1: Changes to primary literature, nomenclature, hydration, antiemetics, and infection prophylaxis V2.0: Adjustment of antineoplastic therapy based on Ladetto et al. 2024. Correction to the antiemesis module for delayed vomiting. V1.0: Cato test done. OptiTemplate test done.
Multiple Myeloma
- Bortezomib 1.3 / Lenalidomide 15, Multiple Myeloma, consolidation, lite PID 37 V1.1 (2026-11-02)V1.1: Protokoll angepasst für VRD-lite Version V1.0: Cato Test erfolgt. V0.1: Die Applikation erfolgt nach dem Studienprotokoll.
- Bortezomib 1.3 / Lenalidomide 15 / Dexamethasone 20, Multiple Myeloma, induction, lite PID 40 V1.1 (2026-11-02)V1.1: Protokoll angepasst für VRD-lite Version V1.0: Cato Test erfolgt. V0.1: Die Applikation erfolgt nach dem Studienprotokoll.
- Lenalidomide 10, Multiple Myeloma, maintenance, lite PID 44 V1.1 (2026-11-02)V1.1: Protokoll angepasst für VRD-lite Version V1.0: Cato Test erfolgt. V0.1: Die Applikation erfolgt nach dem Studienprotokoll.
NHL, B-Cell Type, Diffuse Large Cell
- TEAM - Thiotepa 5 / Etoposide 100 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation PID 406 V2.1 (2026-11-03)V2.1: Changes to primary literature, nomenclature, hydration, antiemetics, and infection prophylaxis V2.0: Adjustment of antineoplastic therapy based on Ladetto et al. 2024. Correction to the antiemesis module for delayed vomiting. V1.0: Cato test done. OptiTemplate test done.
NHL, B-Cell Type, Follicular Grade I-IIIa
- TEAM - Thiotepa 5 / Etoposide 100 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation PID 406 V2.1 (2026-11-03)V2.1: Changes to primary literature, nomenclature, hydration, antiemetics, and infection prophylaxis V2.0: Adjustment of antineoplastic therapy based on Ladetto et al. 2024. Correction to the antiemesis module for delayed vomiting. V1.0: Cato test done. OptiTemplate test done.
NHL, B-Cell Type, Follicular grade IIIb
- TEAM - Thiotepa 5 / Etoposide 100 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation PID 406 V2.1 (2026-11-03)V2.1: Changes to primary literature, nomenclature, hydration, antiemetics, and infection prophylaxis V2.0: Adjustment of antineoplastic therapy based on Ladetto et al. 2024. Correction to the antiemesis module for delayed vomiting. V1.0: Cato test done. OptiTemplate test done.
Stem Cell Transplantation, Autologous
- TEAM - Thiotepa 5 / Etoposide 100 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation PID 406 V2.1 (2026-11-03)V2.1: Changes to primary literature, nomenclature, hydration, antiemetics, and infection prophylaxis V2.0: Adjustment of antineoplastic therapy based on Ladetto et al. 2024. Correction to the antiemesis module for delayed vomiting. V1.0: Cato test done. OptiTemplate test done.
Protocols in Revision
Multiple Myeloma
- HD 7 - Lenalidomide 10 / Dexamethasone 20, Multiple Myeloma, maintenance, cycle 1 PID 43 V1.1
Stem Cell Transplantation, Allogeneic
- Busulfan 3.2 / Cyclophosphamide 60, Allogeneic Stem Cell Transplantation, MAC PID 882 V1.1